PolyNovo 過去の業績

過去基準チェック /36

PolyNovoは、平均年間29.2%の収益成長を遂げていますが、 Medical Equipment業界の収益は、年間成長しています。収益は、平均年間8.3% 37.1%収益成長率で成長しています。 PolyNovoの自己資本利益率は7.3%であり、純利益率は5.1%です。

主要情報

29.2%

収益成長率

29.2%

EPS成長率

Medical Equipment 業界の成長	5.8%
収益成長率	37.1%
株主資本利益率	7.3%
ネット・マージン	5.1%
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

PolyNovo の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

CHIA:PNV 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費
30 Jun 24	103	5	81
31 Mar 24	93	3	74
31 Dec 23	83	2	69
30 Sep 23	75	-2	63
30 Jun 23	66	-5	55
31 Mar 23	59	-6	51
31 Dec 22	53	-7	47
30 Sep 22	48	-4	39
30 Jun 22	42	-1	32
31 Mar 22	38	0	29
31 Dec 21	35	1	26
30 Sep 21	32	-2	27
30 Jun 21	29	-5	27
31 Mar 21	27	-5	26
31 Dec 20	25	-5	25
30 Sep 20	24	-5	23
30 Jun 20	22	-4	21
31 Mar 20	20	-4	19
31 Dec 19	18	-4	17
30 Sep 19	16	-3	15
30 Jun 19	14	-3	12
31 Mar 19	12	-4	11
31 Dec 18	9	-5	9
30 Sep 18	8	-5	9
30 Jun 18	7	-6	8
31 Mar 18	6	-6	8
31 Dec 17	5	-6	8
30 Sep 17	4	-6	8
30 Jun 17	4	-5	7
31 Mar 17	4	-4	6
31 Dec 16	5	-3	5
30 Sep 16	4	-3	5
30 Jun 16	3	-3	5
31 Mar 16	2	-3	4
31 Dec 15	0	-2	4
30 Sep 15	0	-2	3
30 Jun 15	0	-1	3
31 Mar 15	0	-2	3
31 Dec 14	0	-3	3
30 Sep 14	0	-3	3
30 Jun 14	0	-3	3
31 Mar 14	0	-2	3
31 Dec 13	0	-2	2

質の高い収益: PNVは高品質の収益を持っています。

利益率の向上: PNV過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: PNV過去 5 年間で収益を上げており、収益は年間29.2%増加しています。

成長の加速: PNVは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: PNV昨年収益を上げたため、昨年の収益成長をMedical Equipment業界 ( 18.7% ) と比較することは困難です。

株主資本利益率

高いROE: PNVの自己資本利益率 ( 7.3% ) は低いとみなされます。

PolyNovo 過去の業績

過去 基準チェック /36

主要情報

最近の業績更新

Full year 2024 earnings released: EPS: AU$0.008 (vs AU$0.007 loss in FY 2023)

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2022)

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.007 loss in FY 2021)

Recent updates

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 20% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: EPS: AU$0.008 (vs AU$0.007 loss in FY 2023)

Now 23% undervalued

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

Now 21% undervalued

Now 20% undervalued

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Forecast breakeven date pushed back to 2024

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.007 loss in FY 2021)

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

Independent Non-Executive Chairman recently bought AU$434k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Forecast to breakeven in 2023

PolyNovo Limited Provides an Update on its Hernia Device

Non-Executive Independent Director recently sold AU$571k worth of stock

Independent Non-Executive Chairman recently bought AU$721k worth of stock

PolyNovo Announces It has Received Final Independent Review Board

Revenue beats expectations

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in 1H 2020)

New 90-day low: AU$2.42

New 90-day high: AU$3.55

PolyNovo Limited Announces the Breast Device Development Program with Establishment Labs

Non-Executive Independent Director recently sold AU$1.2m worth of stock

PolyNovo Limited Announces US FDA Approves Pivotal Trial IDE

New 90-day high: AU$3.03

New 90-day high: AU$2.74

New 90-day high: AU$2.38

PolyNovo Appoints Innova Medical Oy to Sell Novosorb® BTM in Finland

Independent Non-Executive Chairman recently bought AU$1.0m worth of stock

New 90-day low - AU$2.02

Full year earnings released - AU$0.0063 loss per share

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /36